Reaction
Blood Immunoglobulin M Decreased reporting signals
As of the last recalculation, Blood Immunoglobulin M Decreased appears in 985 FAERS reports alongside 16 co-occurring drug terms. The strongest observed disproportionality signal is OCRELIZUMAB (PRR 70.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ocrelizumab | 172 | 70.8 | 71.0 |
| Human Immunoglobulin G | 61 | 66.5 | 66.7 |
| Ofatumumab | 74 | 50.8 | 50.9 |
| Ibrutinib | 88 | 25.2 | 25.2 |
| Rituximab | 182 | 22.1 | 22.1 |
| Daratumumab | 31 | 16.9 | 16.9 |
| Chlorthalidone | 9 | 16.5 | 16.5 |
| Thalidomide | 20 | 11.7 | 11.7 |
| Belimumab | 16 | 10.8 | 10.8 |
| Busulfan | 8 | 10.8 | 10.8 |
| Desoximetasone | 9 | 10.1 | 10.1 |
| Obinutuzumab | 7 | 9.0 | 9.1 |
| Acalabrutinib | 5 | 8.8 | 8.8 |
| Polatuzumab Vedotin | 4 | 8.7 | 8.7 |
| Dalfampridine | 28 | 8.5 | 8.5 |
| Ixazomib | 10 | 7.4 | 7.4 |